Company’s 36-month beta value is 1.17.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy”, 2 as “overweight”, 2 as “hold”, and 0 as “sell”.
The public float for LXRX is 177.00M, and currently, short sellers hold a 21.22% ratio of that floaft. The average trading volume of LXRX on July 08, 2025 was 5.56M shares.
LXRX stock’s latest price update
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)’s stock price has dropped by -3.13% in relation to previous closing price of $0.9. Nevertheless, the company has seen a gain of 6.32% in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis of clinical study data showing a reduction in hypoglycemic events when sotagliflozin was added to optimized insulin therapy for people with type 1 diabetes (T1D) was presented yesterday during the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois. The ADA emphasizes that hypoglycemia remains an important patient management issue in T1D.
LXRX’s Market Performance
LXRX’s stock has risen by 6.32% in the past week, with a monthly rise of 32.02% and a quarterly rise of 96.93%. The volatility ratio for the week is 10.11% while the volatility levels for the last 30 days are 9.95% for Lexicon Pharmaceuticals Inc. The simple moving average for the past 20 days is 10.20% for LXRX’s stock, with a -0.34% simple moving average for the past 200 days.
Analysts’ Opinion of LXRX
Many brokerage firms have already submitted their reports for LXRX stocks, with Leerink Partners repeating the rating for LXRX by listing it as a “Market Perform”. The predicted price for LXRX in the upcoming period, according to Leerink Partners is $1 based on the research report published on March 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LXRX reach a price target of $10. The rating they have provided for LXRX stocks is “Buy” according to the report published on June 17th, 2024.
Jefferies gave a rating of “Hold” to LXRX, setting the target price at $3 in the report published on March 07th of the previous year.
LXRX Trading at 23.05% from the 50-Day Moving Average
After a stumble in the market that brought LXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.38% of loss for the given period.
Volatility was left at 9.95%, however, over the last 30 days, the volatility rate increased by 10.11%, as shares surge +21.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.92% upper at present.
During the last 5 trading sessions, LXRX rose by +6.32%, which changed the moving average for the period of 200-days by -48.66% in comparison to the 20-day moving average, which settled at $0.7921. In addition, Lexicon Pharmaceuticals Inc saw -47.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Lexicon Pharmaceuticals Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for LXRX
Current profitability levels for the company are sitting at:
- -5.69% for the present operating margin
- 0.98% for the gross margin
The net margin for Lexicon Pharmaceuticals Inc stands at -5.68%. The total capital return value is set at -0.95%. Equity return is now at value -86.09%, with -49.60% for asset returns.
Based on Lexicon Pharmaceuticals Inc (LXRX), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -3.98. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -20.18.
Currently, EBITDA for the company is -184.29 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 9.49. The receivables turnover for the company is 0.66for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.22.
Conclusion
In a nutshell, Lexicon Pharmaceuticals Inc (LXRX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
